Skip to main content

Baseline Study Data Shows Substantial Burden of Moderate-to-Severe Atopic Dermatitis

March 29, 2021

An analysis of the characteristics of 308 adults with moderate-to-severe atopic dermatitis starting or switching systematic therapy provides a real-world picture of the substantial burden of the disease, observed researchers in the Journal of Dermatological Treatment.  

Their study summarized the baseline information of participants enrolled in the ongoing European Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (EUROSTAD), which spans 51 sites in 10 European countries. 

“A comprehensive impact on various domains of health and life is evident,” researchers wrote, “along with atopic and non-atopic comorbidities, despite continuous use of topical drugs, emollients, and systemic therapies. Patients reported a notable impact on nonclinical aspects of life, including mental health, sleep, work, and activities of daily living.” 

Among the 308 patients enrolled, the average age was 37 years, and the average duration of atopic dermatitis was 25 years, according to the study. Some 93% of patients reported use of systemic therapy, and 82% reported one or more atopic comorbidities. 

Disease severity and burden were high, multiple measures showed. Average scores were 3.1 on the Investigator’s Global Assessment, 16.2 on the Eczema Area and Severity Index, 5.5 on the Peak Pruritus Numerical Rating Scale, and 49.8 on the sleep impairment Visual Analog Scale.

Time lost from work averaged 4.1 days a year, and time lost from usual activities averaged 16.8 days annually. 

Per the Hospital Anxiety and Depression Scale, 59% of participants had borderline or clinical levels of anxiety and 63% had borderline or clinical levels of depression. On the Dermatology Life Quality Index, 56.3% of patients reported very or extremely large impairment in overall health-related quality of life. 

“Many participants experienced the added burden of comorbid type-2 inflammatory diseases, with 54% of participants having asthma and 62% experiencing allergic rhinitis at enrollment,” researchers wrote. “This reflects the comorbidity burden of patients with atopic dermatitis requiring a multidisciplinary approach for the treatment of atopic dermatitis.”

Jolynn Tumolo


Bruin-Weller M, Pink AE, Patrizi A, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatolog Treat. 2021;32(2):164-173. doi:10.1080/09546634.2020.1866741

Agree or disagree with an article? Share your professional thoughts on an article you read.

Your Name
3 + 12 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Back to Top